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Abstract
A library of peptidomimetics was assembled combinatorially into dimers on a triazine-based core. The pharmacophore
corresponds to b-turns of the neurotrophin polypeptides neurotrophin-3 (NT-3), nerve growth factor (NGF), or brain-derived
neurotrophic factor (BDNF). These are the natural ligands for TrkC, TrkA, and TrkB receptors, respectively. The linker length
and the side-chain orientation of each monomer within the bivalent mimics were systematically altered, and the impact of
these changes on the function of each ligand was evaluated. While the monovalent peptidomimetics had no detectable
binding or bioactivity, four bivalent peptidomimetics (2c, 2d, 2e, 3f) are selective TrkC ligands with antagonistic activity, and
two bivalent peptidomimetics (1a, 1b) are TrkC and TrkA ligands with antagonistic activity. All these bivalent compounds
block ligand-dependent receptor activation and cell survival, without affecting neuritogenic differentiation. This work adds
to our understanding of how the neurotrophins function through Trk receptors, and demonstrates that peptidomimetics
can be designed to selectively disturb specific biological signals, and may be used as pharmacological probes or as
therapeutic leads. The concept of altering side-chain, linker length, and sequence orientation of a subunit within a
pharmacophore provides an easy modular approach to generate larger libraries with diversified bioactivity.
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Introduction
Neurotrophins are dimeric polypeptide growth factors that
regulate the peripheral and central nervous systems and other
tissues. Neurotrophins (Nerve Growth Factor (NGF), Brain-
Derived Neurotrophic Factor (BDNF), and Neurotrophin-3 (NT-
3)), as well as their cell surface receptors (p75, TrkA, TrkB, and
TrkC) are validated targets for therapeutics in a variety of
pathologies ranging from cancer to neurodegeneration [1–4].
Neurotrophic activities arise from selective ligand binding to the
Trk family of receptors. For example, NGF docks with TrkA,
BDNF binds preferentially to TrkB [5], whereas NT-3 interacts
preferentially with TrkC but can also bind to TrkA [6]. Trk
receptors are typical receptor tyrosine kinases (RTKs), with an
ectodomain, a single transmembrane region, and an intracellular
tyrosine kinase catalytic domain. The extracellular domain of Trk
binds the ligand, leading to activation of the tyrosine kinase,
phosphorylation (pTyr) of the Trk intracellular domain, and signal
transduction cascades involving kinases mitogen-activated protein
kinase (MAPK) and AK mouse thymoma (Akt) [7] that are
activated by phosphorylation. Activated MAPK and Akt regulate
whether a cell enters a growth, or a survival, or a differentiation
pathway [7,8].
In addition, all the neurotrophins bind to the p75 receptor, a
member of the tumor necrosis factor (TNF) receptor superfamily
[9]. The p75 receptor has multiple functions depending on the
cells in which it is expressed, whether a ligand engages it, and
many other variables [10,11]. We sought to develop Trk-selective
binding ligands that exclude p75 signals, and to use these agents to
study receptor biology.
Previously mimicry of neurotrophin b-turns was used to develop
b-turn cyclic peptides [12–15] and b-turn cyclic peptidomimetics
[16,17] of neurotrophins. Recently, the cyclic peptidomimetics
[18] and minimalist mimics [19–21] were assembled into bivalent
mimics based on the hypothesis that this would modify the activity
of the compounds, because the target Trk receptors are tyrosine
kinases that act as dimers.
Here, we further explore the concept of valency, by altering the
linker length and the side-chain orientation of the mimetics within
the bivalent compounds. We generated a combinatorial library of
bivalent peptidomimetics on a triazine core, and a pharmacophore
based on b-turns from NT-3, NGF and BDNF. The resulting
compounds were tested in binding and biological screens which
identified peptidomimetics blocking ligand-dependent receptor
activity of TrkC or TrkA receptors, but which do not affect TrkB
receptors.
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Materials and Methods
Cells
NIH-3T3 cells are mouse fibroblasts that do not express any
neurotrophin receptors. Parental NIH-3T3 cells were transfected
with the indicated receptors. Stable clones of NIH-TrkC express
,100,000 TrkC receptors/cell, NIH-TrkA express ,200,000
TrkA receptors/cell, and NIH-IGF-1R express ,100,000 insulin-
like-growth factor-1 (IGF-1) receptors/cell. These cells, and their
functional responses to the appropriate growth factor have been
reported [17].
Neuronal PC12 express TrkA and p75 neurotrophin receptors
and respond to NGF. The nnr5-TrkC cells are a variant of PC12
that lost TrkA expression, and into which human TrkC cDNA was
Figure 1. Compound design and chemistry. (a) Design of minimalist peptidomimetics with triazole scaffolds, and overlay of triazole-based
mimic with type-I b-turn. (b) Strategy to build triazole-based b-turn mimics by click chemistry. (c) A general scheme to prepare bivalent mimics. (d)
Structures of compounds, A that bind to TrkA.
doi:10.1371/journal.pone.0089617.g001
Figure 2. Relative structure of mimetics within neurotrophin proteins. (a) Distances between hot-spots (highlighted with red, orange, and
yellow) in NT-3. (b) General structures of triazole-based b-turn mimics with long linkers, and lengths of warhead region and linker. (c) Strategy to
build bivalent mimics with different orientation sequences in triazole core.
doi:10.1371/journal.pone.0089617.g002
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stably transfected, and these cells respond to NT-3 [6,22]. The 4-
3.6 cells are B104 rat neuroblastoma stably transfected with
human TrkA cDNA and express equal levels of p75 and TrkA
(TrkA+ p75+) [23]. SY5Y-TrkB cells are human neuroblastoma
SY5Y stably transfected with TrkB.
Cell Survival Assays
The growth/survival profile of the cells were quantified in 96-
well plates using the tetrazolium salt reagent 4-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyltetrazolium bromide (MTT; Sigma) 48–
72 hours after plating; by reading the optical density (OD), as
previously described [24]. Cells cultured in serum-free-medium
(SFM) die by apoptosis with well-established kinetics, but they can
be rescued if they are supplemented with the appropriate growth
factor. NGF protects TrkA-expressing cells from death, and NT-3
protects TrkC-expressing cells from death. Cells did not receive
growth factor supplementation, or were supplemented with
suboptimal or with optimal concentrations of the indicated growth
factor. Test peptidomimetics or vehicle controls were added to the
culture conditions above, for 72 h. Cellular controls are provided
by lack of effect on some cells with effect on other cells. Additional
controls for lack of general toxicity were done by testing
compounds on all cells growing in normal serum conditions (data
not shown). All assays were repeated independently at least three
times (n = 4 for each assay). MTT data are standardized to optimal
dose of neurotrophin = 100% survival, and serum-free medium
(SFM) = 0% survival, using the formula [(ODtest2ODSFM)6100/
(ODoptimal NTF2ODSFM)], with a signal-noise ratio .4.
Primary Neuronal Cultures
Cortex from day 14 C57/BL6 embryos were dissected and
placed on ice-cold HHGN dissection solution (1X HBSS (Cellgro
20-021-CV), 2.5 mM HEPES (pH 7.4), 35 mM glucose, 4 mM
sodium bicarbonate). They were then resuspended in 3 ml of
Trypsin 0.125% in HHGN and incubated for 20 minutes at 37uC.
Trypsinization was stopped with fetal calf serum. The tissue was
collected and resuspended in 1 mL of culture medium, triturated
with 56passes on a 1000P pipette, then 56passes each in a 3 ml
syringe with 18G, 20G and 22G needles. The primary cortical
neurons were counted and plated in a 6 well-plate at 500,000
cells/well in Neurobasal media containing B27 supplement,
Penicillin/Streptomycin and Glutamax. After 48 h neuronal
cultures were treated with vehicle, 2 nM NT-3 alone, or NT-
3+10 mM compounds for 20 min. Cells were then lysed in
detergent for biochemical studies.
Signal Transduction Assays
Cells were stimulated with vehicle (negative control), suboptimal
concentrations of growth factor alone (positive control), or growth
factor plus compounds at 10 mM for 20 min. Detergent lysates
were resolved in SDS-PAGE and analyzed by Western blotting
with anti-phosphotyrosine (pTyr) antibody 4G10 (Upstate Bio-
technology, Lake Placid, NY), anti-phospho-p44/42 MAPK (Thr
202/Tyr204) (Cell Signaling Technology), or anti-phospho-Akt
(Ser473) antibody (Cell Signaling Technology). After stripping,
membrane was probed with anti-actin (Sigma) to standardize
protein loading. Total TrkC was also identified with highly
selective monoclonal antibody 2B7 [6,17,18,22]. Quantification
was done from each membrane versus actin loading control by
densitometric analysis [23].
Neuritogenic Differentiation assay
The assays were performed as described [22]. Briefly, nnr5-
TrkC cells were plated at low density in complete medium and
allowed to adhere to the dish. Then the cells were treated with
vehicle 6 peptidomimetics or the appropriate growth factor 6
peptidomimetics for 72 h. The morphology of the cells was scored
from pictures taken randomly in a blinded fashion. Neurite
outgrowth was determined as percentage of cells with neurites
(defined as length .2 cell bodies).
Fluorescent Activated Cell Scan (FACS) analysis
The assays were performed as described [18]. Briefly, cells
expressing the indicated receptor were first bound, at 4uC, with
biotin-tagged peptidomimetics (20 mM), washed, followed by
addition of fluorescein-avidin at 4uC. After washing, cells were
analyzed by FACScan/CellQuest. The mean channel fluorescence
(MCF) background of NIH-IGF-1R was subtracted to analyze the
specific MCF binding to test cells.
Results
Design and Synthesis of peptidomimetics
Minimalist mimics express only side-chains of secondary
structures and a heterocyclic scaffold is used instead of a peptide
backbone (Figure 1a) [25]. The scaffold gives rigidity to limit the
degrees of freedom for bond rotations but, ideally, without
excluding conformations that correspond the targeted secondary
structures. Our first minimalist mimics were built on triazole-based
scaffolds as b-turn mimic (Figure 1b) [19]. The triazole core was
obtained by click chemistry between azido amino acids and
alkynes having side-chains of amino acids (Figure 1c). The triazole-
based b-turn mimics have piperazine linkers to build bivalent
peptidomimetics that are obtained by SNAr reactions on a triazine.
Combinatorial methods shown in Figure 1d were used to combine
two different monovalent units to give bivalent mimics (hetero- or
homo-bivalent mimics). This combinatorial method has several
advantages. First, combination of n monovalent compounds gives
n(n+1)/2 bivalent compounds; a lot of bivalent mimics can be
made from relatively few monovalent ones. Second, the products
can be formed without using any protecting group on monovalent
components. Finally, the third site in triazine core can be used to
support tags for biological assays, e.g. dyes, biotin, and polyeth-
ylene glycol (PEG). Previously we reported the first triazole-based
b-turn bivalent mimics A selectively bind to TrkA just as NGF
does, but their activities in cellular assays are weak. Thus, this
present study focused on discovering related compounds to
improve binding to ‘‘Trk’’ receptors and the activities of these
compounds in cellular assays.
In particular, we were interested in using long-linkers between
triazole core and triazine core in bivalent mimics to provide more
distance variation for separation of the monovalent units on
binding. Distances between hot-spots in neurotrophins are from
10 A˚ to 43 A˚ (Figure 2a). Consequently, we reasoned that if each
monovalent mimic were connected to flexible chains of about
15 A˚ length, the total separation would be about 41 A˚ maximum,
and the warhead regions could orient like any pair of turns in
neurotrophins (Figure 2b). This strategy might especially increase
the chances for mimicry of b-turns that are far from each other.
While a flexible linker has an entropic cost, the cooperative
binding of a bivalent ligand could compensate and enhance the
affinity.
Another new line of investigation for this study was to use side-
chains on the peptidomimetics that correspond exactly to the i+1
and i+2 residues in the neurotrophins turn regions [19]. Thus, in
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Figure 3. Structures of antagonists for TrkC or TrkA.
doi:10.1371/journal.pone.0089617.g003
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the present work, seven dipeptide sequences corresponding to i+1
and i+2 residues in the neurotrophins were targeted; IK, EK, and
GK from NGF, MS and SK from BDNF, and IR and TG from
NT-3 (Table S1 in Information S1, highlighted with red).
Sequences that contain asparagine, e.g. NN or NK from NGF
and NT-3 were not chosen because of synthetic difficulty.
A third variable tested in this study was the orientation of the
side-chains in the mimics. Monovalent mimics with the long
linkers were prepared in two different orientations, e.g. ‘‘forward’’
and ‘‘opposite’’ sequences. The forward sequence follows the
orientation of natural ligands, N- to C-terminal (R1R2 and
R3R4 = i+1-i+2, e.g. TG), but the opposite sequence has the
orientation of C- to N-terminal (R1R2 and R3R4 = i+2-i+1, e.g.
GT). Therefore, bivalent mimics by combination of the monova-
lent mimics were prepared in three different library sets; library 1
(forward only): R1R2 and R3R4 = i+1-i+2 and i+1-i+2, e.g. TG-
TG, library 2 (opposite only): R1R2 and R3R4 = i+2-i+1 and i+2-
i+1, e.g. GT-GT, and library 3 (forward-opposite): R1R2 and
R3R4 = i+1-i+2 and i+2-i+1, e.g. TG-GT as Figure 2c.
A library of 120 bivalent compounds with either a triethylene
glycol (TEG) based label or biotin label was prepared from 14
monovalent compounds and morpholine using a procedure similar
to a previously reported one [19,20]. The morpholine was used as
a control for triazole-based mimics, and a linker part.
Figure 4. Selective antagonism of ligand-dependent cell survival. NIH-3T3 cells expressing either TrkA or TrkC or IGF-1R were cultured in
SFM supplemented with the indicated peptidomimetic (10 mM) with optimal (a) or suboptimal (b) concentrations of the appropriate growth factor
for 72 h. Survival was measured in MTT assays, and was calculated relative to optimal growth factor-mediated survival (100%). Results shown are
average + SEM, from at least three independent experiments. One-way ANOVA, p,0.05 considered significant. All ‘‘hits’’ shown were significant for
inhibition of TrkC, only 1a and 1b ‘‘hits’’ were significant for inhibition of TrkA.
doi:10.1371/journal.pone.0089617.g004
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The modified reaction schemes for monovalent and bivalent
peptidomimetics are described in Supplemental (Tables S2 and S3
in Information S1). The purification and characterization proce-
dures and data (HPLC and 1H-NMR and 13C-NMR) for
monovalent mimics are in Supplemental (Section C in Informa-
tion S1). The morpholine linker was used as a control for triazole-
based mimics.
Selective inhibition of TrkC and TrkA mediated cell
survival
A total of 134 monomeric and the corresponding bivalent
peptidomimetics including control compounds were tested in cell
survival assays. Cells undergo apoptotic death when cultured in
serum-free medium (SFM). Growth-factor protection from death
in SFM is dose-dependent and time-dependent. Optimal concen-
trations of growth factor (4 nM) afford maximal protection
standardized to 100%. Suboptimal concentrations of growth
factor (0.2 nM) protect at ,30–40% of maximal.
The peptidomimetics were tested for their effect on NGF or
NT-3-mediated survival. From the 134 compounds, 1a, 1b, 2c,
2d, 2e, 3f (Figure 3) significantly reduce the survival of NIH-TrkC
cells responding to the cognate growth factor NT-3 at both
optimal and suboptimal doses (Figure 4) (p,0.05). In counter-
assays testing NIH-TrkA cells responding to the cognate growth
factor NGF, compounds 2c, 2d, 2e, 3f have no effect (hence they
are selective for TrkC). However, compounds 1a, 1b significantly
reduce the survival of NIH-TrkA cells induced by NGF at both
optimal and suboptimal doses (Figure 4) (p,0.05).
In controls, none of these compounds had an effect on the
survival of NIH-IGF-1R cells responding to a different growth
factor, IGF-1 (Figure 4a). Lack of effects on the growth of NIH-
IGF-1R cells responding to IGF-1 indicate a selective reduced
metabolic activity of NIH-TrkC cells responding to NT-3 or NIH-
TrkA cells responding to NGF. This is likely due to reduced TrkC
or TrkA signaling.
The selectivity of the inhibition of ligand-dependent survival
suggests lack of generalized toxicity. In addition, lack of general
toxicity was further determined because when the three cells lines
are grown in normal serum there is no effect on growth (data not
shown) and when the three cells lines are grown in serum-free
medium without supplemented growth factors there is not
accelerated death above that seen in serum-free medium (data
not shown).
Co-expression of p75 does not influence the antagonism
of peptidomimetics
MTT survival data in nnr5-TrkC cells (expressing TrkC and
p75) and rat neuroblastoma 4-3.6 cells (expressing TrkA and p75)
are similar to the data in fibroblast cells NIH-TrkC, and NIH-
TrkA, indicating that p75 co-expression does not interfere in the
antagonism of survival by these peptidomimetics (Figure 5).
Selective inhibition of TrkC and TrkA-mediated signal
transduction
To confirm the antagonistic activity of these compounds we
analyzed signal transduction in biochemical assays. The tyrosine
phosphorylation of the Trk receptors (p-Trk), the phosphorylation
of Akt (p-Akt), and the phosphorylation of MAPK (p-MAPK) were
studied by western blots of cell lysates prepared after stimulation of
cells with the appropriate growth factor 6 compounds for 20 min.
The 20 min time point was chosen because NT-3 and NGF are
known to induce sustained activity of these signal pathways, but
without causing downregulation or internalization of the Trk
receptors that could affect the overall signals [22].
In NIH-TrkC cells NT-3 induces strong p-TrkC, p-Akt and p-
MAPK. 1a, 1b, 2c, 2d, 2e, 3f decreased significantly these
Figure 5. Co-expression of p75-receptors does not influence antagonism of ligand-dependent cell survival. Neuronal nnr5-TrkC cells
expressing (TrkC and p75) and 4-3.6 cells (TrkA and p75) were cultured in SFM supplemented with the indicated peptidomimetics (10 mM) with or
optimal concentration of the appropriate growth factor for 72 h. Survival was measured in MTT assays, and was calculated relative to optimal growth
factor-mediated survival (100%). Results shown are average + SEM, from at least three independent experiments. One-way ANOVA, p,0.05
considered significant. All ‘‘hits’’ shown were significant for TrkC, only 1a and 1b ‘‘hits’’ were significant for inhibition of TrkA.
doi:10.1371/journal.pone.0089617.g005
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ligand-dependent signals (p,0.05). Similar results were obtained
in nnr5-TrkC expressing p75, indicating that p75 co-expression
may not interfere with antagonism by the compounds. However,
the inhibition of TrkC signals was significantly more pronounced
in nnr5-TrkC compared versus NIH-TrkC cells (Figure 6). This
Figure 6. Antagonists of TrkC or TrkA receptor inhibit ligand-dependent signaling pathways in cell lines. (a) NIH-TrkC (a), nnr5-TrkC (b),
NIH-TrkA (c), NIH-IGF-1R (d) and SY5Y-TrkB (e) cells were exposed to the indicated peptidomimetic (10 mM) and NT-3 (0.2 nM) (a, b), NGF (0.2 nM) (c),
IGF-1 (10 nM) (d) and BDNF (0.2 nM) (e) for 20 min. Detergent lysates were analyzed by Western blotting with anti-pTyr mAb 4G10 or anti-phospho-
MAPK or anti-phospho-Akt. After stripping, membrane was re-probed with anti-actin antibodies to standardize loading. (b) Quantification of p-TrkC
in NIH-TrkC and nnr5-TrkC by densitometry from 3 independent experiments. Data are expressed as the mean + SEM relative to growth factor. One-
way ANOVA, p,0.05 considered significant. All ‘‘hits’’ shown were significant for inhibition of TrkC compared versus drug-untreated. * indicates
differences in efficacy comparing the two cell lines.
doi:10.1371/journal.pone.0089617.g006
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may be because NIH-TrkC cells express .3-fold more TrkC
receptors/cell than nnr5-TrkC cells [17,20].
As expected from the cell survival assays, 2c, 2d, 2e, 3f do not
reduce the p-TrkA activation by NGF. However, 1a, 1b reduce p-
TrkA by NGF. In controls, none of the compounds affect the
activating signals that IGF-1 affords through IGF-1R (Figure 6).
In further counter-assays, we also studied TrkB receptor
activation by BDNF in neuronal cells SY5Y-TrkB. These
peptidomimetics do not reduce the pTrkB activation by BDNF
(Figure 6a), further indicating their selectivity for TrkC and TrkA.
These biochemical data are consistent with the bioassays, and
indicate that an NT-3 or NGF derived peptidomimetics can
inhibit NT-3-dependent or NGF-dependent activation and
tyrosine phosphorylation of the target receptor. Reduced signals
downstream of the receptor result in lower cell survival in
bioassays.
To verify the data above, similar assays were done using
primary neuronal cultures prepared from the cortex of embryonic
day 14 mice (Figure 7). These neurons express TrkC (Figure 7b).
Treatment with NT-3 (2 nM for 20 min) induces biochemical
signals (p-TrkC, p-PLCc, p-AKT) that are inhibited by co-
treatment with 10 mM TrkC antagonistic compounds 1a or 3f
(Figure 7c). In the absence of NT-3 compounds did not induce
signals (Figure 7c), suggesting that they are not partial agonists or
inverse antagonists.
Lack of effect in differentiation assays
While 1a, 1b, 2c, 2d, 2e, 3f reduce the survival induced by
NT-3, they do not inhibit the NT-3-induced differentiation of
neuronal cells nnr5-TrkC. Representative pictures from nnr5-
TrkC cells treated with compound 1b are shown (Figure 8).
Binding assays with biotin-tagged compounds
The peptidomimetics were tagged with biotin in order to
perform binding studies. The new biotin-compounds are named
1a9, 1b9, 2c9, 2d9, 2e9, 3f9 and are respectively equivalent to 1a,
1b, 2c, 2d, 2e, 3f.
FACS binding indicated that 1a9, 1b9, 2c9, 2d9, 2e9, 3f9 bind
preferentially to TrkC receptor. 1a9, 1b9 also bind to TrkA but to
a lesser degree than TrkC (Figure 9a).
To ascertain that replacement of TEG with biotin has no
influence on the function of the compounds, 1a9, 1b9, 2c9, 2d9,
2e9, 3f9 were also tested in biochemical and biological assays
already described. The results are equivalent whether the
compounds carry a TEG or a biotin tag (Figure 9b).
Discussion
We report on the biological characterization of a library of 134
triazole-based peptidomimetics with the potential to mimic NT-3,
NGF, or BDNF because they analog relevant b-turn sequences
(i+1-i+2). Six bivalent mimics in the library showed biological
activities for TrkA or TrkC, but none of the monovalent mimics
and a morpholine bivalent mimic that was used as a control for
triazole-based mimics showed any significant activities for Trk
receptors. Bivalent mimics 2c, 2d, 2e, 3f are selective TrkC
ligands, and 1a, 1b are TrkC and TrkA ligands in binding assays
(FACS). The compounds act as antagonists in bioassays (survival in
SFM) and in biochemical assays (receptor signal transduction).
These peptidomimetics do not block the activity of IGF-1R or
TrkB, and are not affected by p75 co-expression.
In previous work, we reported triazole-based b-turn bivalent
mimics with related sequences in the b-turn region of neurotro-
phins, connected by a relatively rigid piperazine linker [19]. Four
peptidomimetics showed selective binding activity for TrkA.
However, the compounds did not show significant cellular activity
in bioassays. To improve the cellular activity, and selectivity for
Trk receptors, we modified the triazole-based b-turn mimics to use
a long alkyl linker, i+1-i+2 sequences, and sequence orientation.
We expected the long linker would give more chances to mimic b-
turns that are far from each other. In direct comparison between
the previous library and the present library, a triazole-based
bivalent mimic with the same residue set, RI-TG, with 2d, but a
short linker (only piperazine linker) did not bind to any Trk
receptors [19].
In addition, we hypothesized that amino acid side-chains
corresponding to b-turn in neurotrophins might give selectivity of
the compounds for Trk receptors. Comparison between sequences
of active compounds and neurotrophins are summarized in
Table 1.
Compound 1b binds to both TrkC and TrkA and have
dipeptide sequences corresponding to i+1-i+2 of NGF and NT-3.
Figure 7. Antagonists of TrkC receptor modulate ligand-
dependent signaling pathways in primary neuronal cultures.
Primary neuronal cultures were prepared from the cortex of embryonic
day 14 mice (ed 14). (A) representative picture of a culture. (B) TrkC is
detected in western blots of lysates obtained from these neurons, using
anti-TrkC mAb 2B7. (C) Treatment with NT-3 (2 nM for 20 min) induces
biochemical signals (p-TrkC, p-PLCc, p-AKT) that are inhibited by co-
treatment with compounds 1a or 3f (10 mM). In the absence of NT-3,
the compounds did not have an effect on signals. Control b-tubulin III is
loading standard.
doi:10.1371/journal.pone.0089617.g007
Figure 8. Antagonists do not affect ligand-dependent neur-
itogenesis. Cells expressing TrkC and p75 (nnr5-TrkC) were plated in
full medium 6 neurotrophin 6 peptidomimetics (10 mM). Fields were
photographed 72 h later. Neurite outgrowth was determined as
percentage of cells with neurites (defined as length .2 cell bodies).
Representative pictures from nnr5-TrkC for compound 1b are shown.
doi:10.1371/journal.pone.0089617.g008
Modular Generation of Receptor Ligands
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Compound 1a binds to both TrkC and TrkA also but has a
dipeptide that corresponds to a turn in NT-3 (e.g. it does not have
NGF sequences). Since NT-3 does bind to TrkA (albeit with lower
affinity than NGF) it is possible that this dipeptide is involved in
the binding. Both 1a and 1b follow the orientation found in the
natural ligands (sequences i+1 and i+2, N-terminal to C-terminal).
Compounds 2c and 2d, which selectively bind to TrkC, have
sequences corresponding to NT-3, the natural ligand of TrkC.
However, 2e and 3f which also bind to TrkC selectively have
sequences corresponding to NGF and BDNF, and this was
unexpected because NGF binds TrkA and BDNF bind TrkB. This
suggests that the sequences at the b-turns of neurotrophins may be
promiscuous (Table S1 in Information S1). but constrained either
by their orientation or by the overall conformation of the protein.
Overall, the data suggest that the orientation of the b-turn side-
chains are relevant to the selectivity of these compounds.
Figure 9. Biotinylated peptidomimetics have similar activity as untagged compounds. (a) Cells expressing the indicated receptor were
exposed at 4uC to biotinylated ligand (20 mM), followed by fluorescein-avidin. After washing, cells were analyzed by FACScan/CellQuest. The
background MCFs of NIH-IGF-1R were subtracted to analyze the specific MCF binding to test cells. Results shown are average MCF+SEM, n= 3
independent experiments. ANOVA, p,0.05 considered significant. All ‘‘hits’’ shown were significant for TrkC, only 1a9 and 1b9 ‘‘hits’’ were significant
for TrkA. (b) Biotinylated peptidomimetics were tested in cell survival bioassays. NIH-3T3 cells expressing either TrkA or TrkC receptor were cultured in
SFM supplemented the indicated peptidomimetics (5 mM) with or without optimal concentrations of the appropriate growth factor for 72 h, as
indicated. Survival was measured in MTT assays, and was calculated relative to optimal growth factor-mediated survival (100%). Results shown are
average + SEM, from at least three independent experiments. One-way ANOVA, p,0.05 considered significant (a, b). All ‘‘hits’’ shown were significant
for inhibition of TrkC, only 1a9 and 1b9 ‘‘hits’’ were significant for inhibition of TrkA.
doi:10.1371/journal.pone.0089617.g009
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Consistent with the concept that orientation affects selectivity 2c
(GT-EK) and 2d (RI-TG) share one set of side-chains but in the
opposite orientation (sequences i+2 and i+1, C-terminal to N-
terminal), and inversion of the sequence of 1a (SK-IK) binding
both TrkC and TrkA results in 3f (KS-KI) with selectivity to
TrkC. However, their hybrid mimics (SK-KI and KS-IK) do not
show any significant binding or activity for the receptors.
Previously, we reported NT-3 mimics with partial agonistic
activity. They are b-turn cyclic peptidomimetics [17,26] with ring-
fused C1- motif or b-turn triazole-based minimalist mimics [20]
that have extra amino group on the triazole core, and side-chains
that were commonly found at hot-spot interactions in general.
Changes of the pharmacophores, such as the simplest triazole-
based minimalist mimics, combinatorial assembly, different side-
chains, and longer linker length, in the present work gave different
biological effect, partial antagonists of TrkC, or both TrkC and
TrkA.
Antagonism of ligand-dependent activation can be most easily
explained in terms of competitive antagonism, meaning that the
small molecule prevents the binding of the natural ligand to the
receptor. Biological data are consistent with this notion. The fact
that these peptidomimetics do not reduce the baseline TrkC or
TrkA receptor activity in the absence of NT-3 or NGF further
suggest that they act as ligand competitors. Unfortunately labeled
NT-3 was not of a quality sufficient to perform direct competition
studies.
The antagonism of these peptidomimetics is limited to ligand-
dependent cell survival, because they do not affect neuritogenic
differentiation. Based on the literature, we offer two possible
explanations.
First, there are at least two receptor ‘‘hot-spots’’ associated with
discrete biological activities [6,22,27]. Agonists binding to such
hot-spots can activate one pathway (e.g. the ‘‘survival hot-spot’’)
but not to another (e.g. the ‘‘differentiation hot-spot’’), and vice
versa [17,20]. Thus, it is possible that the mimetics herein prevent
ligand binding to (or ligand activation of) one hot-spot of the
receptor (e.g. the ‘‘survival hot-spot’’) but not the other (e.g. the
‘‘differentiation hot-spot’’).
Second, the discriminating effect upon survival versus differen-
tiation may be related to the kinetics of receptor activation leading
to each biological effect. Fast and transient kinetics of receptor
activation transduce signals leading to survival, whereas slow and
sustained kinetics of receptor activation transduce signals leading
to differentiation [28,29]. We speculate that the antagonists
perhaps alter the kinetics of receptor activation, or perhaps alter
the kinetics of receptor endocytosis or recycling [30], in such a way
that survival is inhibited.
Conceptually, we demonstrate that altering side-chain, linker
length, and sequence orientation of a neurotrophin pharmaco-
phore can supply an easy modular approach to generate larger
libraries with diversified bioactivity. We propose that the approach
may be applicable to other target peptides and growth factors.
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